Idelalisib in CLL and iNHL

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses treatment with idelalisib for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL)

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses treatment with idelalisib for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL).

Clinical Pearls:

  • Idelalisib is a PI3K-delta-specific inhibitor
  • Idelalisib demonstrated promising results in various trials in CLL and iNHL
  • Idelalisib has little side effects, is very well tolerated, and improves quality of life